Merck's SWOT analysis: stock faces keytruda patent cliff, pipeline potential

Merck (MRK) is at a critical juncture, facing the impending 2028 patent expiration of its blockbuster Keytruda, which delivered strong Q4 2024 sales of $7.84 billion. However, the company's 2025 revenue and EPS guidance were negatively impacted by a significant pause in Gardasil sales in China, leading to a 3% and 2.2% miss against consensus, respectively. Merck's future growth hinges on successfully commercializing its promising pipeline, notably in Antibody-Drug Conjugates (ADCs) and KRAS inhibitors, and extending Keytruda's lifecycle with a subcutaneous formulation, despite an ongoing patent dispute. The company's ability to diversify revenue streams and potentially pursue strategic M&A will be crucial to offset the anticipated post-Keytruda patent cliff revenue decline and maintain its market position.

Analysis

Merck's financial position presents a dichotomy for investors, with strong current performance overshadowed by significant future uncertainties. While the company exceeded Q4 2024 consensus expectations with a 1% revenue beat and a 7% EPS beat, driven by Keytruda's robust sales of $7.84 billion (a 3% beat), this positive result is heavily counteracted by weak forward guidance. The company's fiscal year 2025 revenue and EPS forecasts are 3% and 2.2% below consensus, respectively, a direct consequence of pausing Gardasil sales in China, which already missed Q4 sales estimates by 1%. This highlights immediate operational vulnerabilities just as the market scrutinizes Merck's long-term strategy for navigating the 2028 patent expiration of Keytruda, an event expected to trigger a 10-20% sales decline. The company's bull case hinges on its pipeline, featuring promising assets like the ADC sac-TMT (72% ORR in TNBC) and KRAS inhibitor MK-1084. However, the development of a subcutaneous Keytruda formulation, a key lifecycle extension strategy, is complicated by an ongoing patent dispute with Halozyme, adding another layer of risk to an already complex outlook.

Key Decisions for Investors

• Investors should closely monitor clinical trial results and regulatory milestones for key pipeline assets, particularly the ADC sac-TMT and KRAS inhibitor MK-1084, as their success is critical to mitigating the post-2028 Keytruda revenue cliff.
• Given the weak 2025 guidance, it is prudent to factor in the near-term earnings pressure from the Gardasil sales disruption in China and watch for any signs of a resolution or further impact on international sales.
• The ongoing patent litigation with Halozyme over the subcutaneous Keytruda formulation represents a significant binary event; a favorable outcome could materially improve Merck's long-term outlook, while a loss would heighten patent cliff concerns.
• Consider Merck's conservative M&A strategy a key risk factor, and treat any pivot towards more aggressive, strategic business development as a potential catalyst for de-risking the company's heavy reliance on its internal pipeline.